The FDA panel, in a 13-0 vote, agreed the drug fidaxomicin was safe and effective in treating C. diff. However, there was disagreement among the panelists over whether the drug was able to prevent infections in the future, according to the news report. The panelists also said the drug should include a warning label mentioning potential risks to patients who are pregnant or have weak immune systems, according to the news report.
Despite the panel’s unanimous backing, the FDA is not obligated to fully approve the drug. The FDA is expected to make a decision about the drug’s final clearance by May 30.
Read the news report about Optimer’s drug fidaxomicin.
Read other coverage about C. diff.:
– Previous Health Facility Contact a Risk Factor for C. Diff Infection
– 6 Common Misconceptions About Surgery Center Sterilization
– Hines VA CDI Severity Score Index Shows Strongest Correlation for Predicting Severe C. Diff Cases
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.